Published in Nat Med on March 17, 2003
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain | NCT00287248
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Microglia in neurodegenerative disease. Nat Rev Neurol (2010) 5.83
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med (2008) 3.15
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Cerebral amyloid angiopathy in the elderly. Ann Neurol (2011) 2.84
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest (2005) 2.51
Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement (2009) 2.46
Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med (2005) 2.43
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med (2012) 2.38
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation (2005) 2.23
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry (2005) 2.15
Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest (2004) 2.13
The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol (2006) 2.10
Biomarkers of Alzheimer disease in plasma. NeuroRx (2004) 2.02
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol (2008) 1.74
Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci (2008) 1.73
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2007) 1.73
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Alzheimer disease. Dis Mon (2010) 1.64
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell (2007) 1.61
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther (2009) 1.57
Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A (2011) 1.56
The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.55
Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One (2009) 1.52
Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron (2015) 1.49
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol (2008) 1.47
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Immunotherapy for Alzheimer's disease. J Intern Med (2011) 1.43
Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo? Eur J Nucl Med Mol Imaging (2004) 1.42
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A (2009) 1.37
Protease-activated drug development. Theranostics (2012) 1.36
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res (2009) 1.34
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience (2006) 1.31
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.30
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.29
Pathogenesis of Alzheimer's disease. Clin Interv Aging (2007) 1.27
Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res (2009) 1.26
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm (Vienna) (2010) 1.22
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Transgenic models of Alzheimer's disease: learning from animals. NeuroRx (2005) 1.21
Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem (2009) 1.20
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol (2007) 1.19
Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J Alzheimers Dis (2010) 1.19
Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res (2007) 1.18
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A (2007) 1.17
Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings. Neuroradiology (2013) 1.17
Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis (2010) 1.17
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol (2005) 1.14
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Cerebral amyloid angiopathy: emerging concepts. J Stroke (2015) 1.14
DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.12
Bapineuzumab. Expert Opin Biol Ther (2010) 1.12
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol (2004) 1.11
The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol (2010) 1.11
Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol (2008) 1.11
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett (2007) 1.09
Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol (2010) 1.09
Longitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers. Neurology (2011) 1.09
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol (2009) 1.08
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet (2011) 6.09
Microglia in neurodegenerative disease. Nat Rev Neurol (2010) 5.83
Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med (2012) 5.64
Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol (2007) 4.13
Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med (2007) 4.11
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet (2008) 3.11
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation (2008) 2.27
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust (2003) 2.23
The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry (2007) 2.23
Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol (2005) 2.16
Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis (2002) 2.14
Rural doctors and rural backgrounds: how strong is the evidence? A systematic review. Aust J Rural Health (2003) 1.95
Assessment for selection for the health care professions and specialty training: consensus statement and recommendations from the Ottawa 2010 Conference. Med Teach (2011) 1.86
Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry (2004) 1.82
Giant tumefactive perivascular spaces. AJNR Am J Neuroradiol (2005) 1.80
Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med (2003) 1.79
Sensory stimulation in dementia. BMJ (2002) 1.71
Inequitable provision of optimal services for patients with chronic heart failure: a national geo-mapping study. Med J Aust (2007) 1.67
Skin cancer surgery in Australia 2001-2005: the changing role of the general practitioner. Med J Aust (2007) 1.66
Dealing with "rogue" medical students: we need a nationally consistent approach based on "case law". Med J Aust (2008) 1.52
Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int J Geriatr Psychiatry (2002) 1.52
Coping with increasing numbers of medical students in rural clinical schools: options and opportunities. Med J Aust (2008) 1.49
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol (2011) 1.41
Community participation in organising rural general practice: is it sustainable? Aust J Rural Health (2006) 1.38
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord (2007) 1.38
Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging (2004) 1.36
Association between HIV-1 infection, the etiology of genital ulcer disease, and response to syndromic management. Sex Transm Dis (2003) 1.36
Factors associated with rural practice among Australian-trained general practitioners. Med J Aust (2003) 1.35
The relationship between resilience and personality traits in doctors: implications for enhancing well being. PeerJ (2013) 1.35
Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol (2010) 1.31
A time bomb of cardiovascular risk factors in South Africa: results from the Heart of Soweto Study "Heart Awareness Days". Int J Cardiol (2008) 1.29
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol (2006) 1.29
Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis Assoc Disord (2005) 1.29
Laboratory productivity and the rate of manual peripheral blood smear review: a College of American Pathologists Q-Probes study of 95,141 complete blood count determinations performed in 263 institutions. Arch Pathol Lab Med (2006) 1.28
Mapping the emergence of heart disease in a black, urban population in Africa: the Heart of Soweto Study. Int J Cardiol (2006) 1.28
Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry (2010) 1.26
Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement (2010) 1.24
Dermatoscopy in routine practice - 'chaos and clues'. Aust Fam Physician (2012) 1.23
Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One (2012) 1.22
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. Int J Geriatr Psychiatry (2002) 1.18
Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuroimmune Pharmacol (2013) 1.18
Signalling between the hindbrain and paraxial tissues dictates neural crest migration pathways. Development (2002) 1.16
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol (2009) 1.16
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry (2009) 1.14
Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement (2010) 1.11
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord (2007) 1.10
Modelling long-term effects of IGRs on honey bee colonies. Pest Manag Sci (2007) 1.07
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. PLoS One (2010) 1.07
Application of geographic modeling techniques to quantify spatial access to health services before and after an acute cardiac event: the Cardiac Accessibility and Remoteness Index for Australia (ARIA) project. Circulation (2012) 1.04
Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain (2013) 1.03
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol (2010) 1.01
Bullying in the Australian medical workforce: cross-sectional data from an Australian e-Cohort study. Aust Health Rev (2012) 1.00
Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain. Aging Cell (2013) 0.99
Hot summers and heart failure: seasonal variations in morbidity and mortality in Australian heart failure patients (1994-2005). Eur J Heart Fail (2008) 0.99
The safety and tolerability of donepezil in patients with Alzheimer's disease. Br J Clin Pharmacol (2004) 0.97
Energy dispersive X-ray diffraction as a means to identify illicit materials: a preliminary optimisation study. Appl Radiat Isot (2007) 0.95
Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2004) 0.95
Does health service utilisation vary by remoteness? South Australian population data and the Accessibility and Remoteness Index of Australia. Aust N Z J Public Health (2004) 0.94
Prospective study of wound infections in dermatologic surgery in the absence of prophylactic antibiotics. Dermatol Surg (2006) 0.94
The phagocytic capacity of neurones. Eur J Neurosci (2007) 0.93
Are N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience. Value Health (2008) 0.93
Interaction of Neisseria meningitidis with human meningeal cells induces the secretion of a distinct group of chemotactic, proinflammatory, and growth-factor cytokines. Infect Immun (2002) 0.93
Prolonged effects of a home-based intervention in patients with chronic illness. Arch Intern Med (2006) 0.93
Influence of HIV-1 coinfection on effective management of abnormal vaginal discharge. Sex Transm Dis (2003) 0.92
Different meningitis-causing bacteria induce distinct inflammatory responses on interaction with cells of the human meninges. Cell Microbiol (2004) 0.92
The effects of four insect growth-regulating (IGR) insecticides on honeybee (Apis mellifera L.) colony development, queen rearing and drone sperm production. Ecotoxicology (2005) 0.91
No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2011) 0.91
Excellence in teaching and learning in medical schools. Med Teach (2011) 0.91
Uncovering a hidden epidemic: a study of the current burden of heart failure in Australia. Heart Lung Circ (2004) 0.91
The impact of subspecialization and dermatoscopy use on accuracy of melanoma diagnosis among primary care doctors in Australia. J Am Acad Dermatol (2012) 0.90
Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases. Addiction (2009) 0.90
Effectiveness of 5-fluorouracil treatment for actinic keratosis--a systematic review of randomized controlled trials. Int J Dermatol (2009) 0.90
Roles of erbB4, rhombomere-specific, and rhombomere-independent cues in maintaining neural crest-free zones in the embryonic head. Dev Biol (2004) 0.90
Empiric validation of the rural Australian Medical Undergraduate Scholarship 'rural background' criterion. Aust J Rural Health (2005) 0.90
The difficult problem: assessing medical students' professional attitudes and behaviour. Med J Aust (2010) 0.89
A multi-center study of ACE and the risk of late-onset Alzheimer's disease. J Alzheimers Dis (2011) 0.89
The clinical consequences and challenges of hypertension in urban-dwelling black Africans: insights from the Heart of Soweto Study. Int J Cardiol (2009) 0.89
Interventions for cutaneous Bowen's disease. Cochrane Database Syst Rev (2013) 0.88
Evidence-based practice in rural and remote clinical practice: where is the evidence? Aust J Rural Health (2003) 0.88
Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun (2007) 0.88
Molecular pathogenesis of subarachnoid haemorrhage. Int J Biochem Cell Biol (2003) 0.88
Chronic heart failure beyond city limits. Rural Remote Health (2005) 0.88
AD2000: design and conclusions. Lancet (2004) 0.87
Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. J Alzheimers Dis (2010) 0.87
Treatment of maternal syphilis in rural South Africa: effect of multiple doses of benzathine penicillin on pregnancy loss. Trop Med Int Health (2004) 0.87
Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord (2009) 0.87
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials (2009) 0.86
Cerebral amyloid angiopathy: both viper and maggot in the brain. Ann Neurol (2005) 0.86
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord (2011) 0.86